Erlotinib-associated trichomegaly.
A 70-year-old woman presented with a corneal ulcer resulting from aberrant and exuberant eyelash growth. She had recently been diagnosed with recurrent non-small-cell lung cancer for which she had begun a chemotherapeutic regimen that included erlotinib HCl. After several months of treatment, she noted the onset of escalating ocular irritation, which culminated in her presentation. Examination of her ocular adnexa revealed coarse, brittle, irregular aberrant eyelash growth. She has been successfully treated with regular epilation and eyelash trimming and has remained symptom free.
Lane
Katherine
K
Oculoplastic Service, Wills Eye Hospital, Jefferson University Hospital Center, Philadelphia, Pennsylvania 19107, USA. katelane@verizon.net
Goldstein
Scott M
SM
D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003320:Corneal Ulcer / Q000209:etiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005140:Eyelashes / Q000187:drug effects*; D005260:Female; D006204:Hair Removal; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced* / Q000628:therapy; D008175:Lung Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors